Diazon Pharmaceuticals
Marseille Pharmaceuticals specializes in immunotherapy treatments for cancer, focusing on innovative approaches that act on the immune system to combat various types of cancer, including melanoma and lung cancer. They emphasize distinct mechanisms of action, safety, and efficacy in their pharmaceutical developments.
Industries
biotechnology
health-care
Nr. of Employees
small (1-50)
Diazon Pharmaceuticals
Montréal, Quebec, Canada, North America
Products
Microtubule-targeting anticancer therapeutic candidate
An investigational anticancer compound that binds tubulin via a distinct mechanism, developed for treatment of melanoma and non-small cell lung cancer; shows preclinical efficacy as monotherapy and in combination, and lacks peripheral neuropathy in a rat model within the effective dose range.
Microtubule-targeting anticancer therapeutic candidate
An investigational anticancer compound that binds tubulin via a distinct mechanism, developed for treatment of melanoma and non-small cell lung cancer; shows preclinical efficacy as monotherapy and in combination, and lacks peripheral neuropathy in a rat model within the effective dose range.
Expertise Areas
- Oncology drug discovery and preclinical development
- Microtubule-targeting agent research
- Preclinical pharmacology and toxicology
- Translational in vivo tumor modeling (xenograft, PDX, GEMM)
Key Technologies
- Tubulin-binding small molecules
- Microtubule-targeting agents (MTA)
- Cell-line xenograft models
- Patient-derived xenograft (PDX) models